Evidence map›Paper›PMID 37442822›Full record

Observational studyAnnals of hematology2023

Association between ABO blood groups and SARS-CoV-2 infection in blood donors of Puglia region.

Alessia Sticchi Damiani, Antonella Zizza, Federico Banchelli, Maddalena Gigante, Maria Lucia De Feo, Angelo Ostuni, Valerio Marinelli, Serena Quagnano, Pierpaolo Negro, Nicola Di Renzo and 2 more

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Alessia Sticchi Damiani *Immunohaematology and Transfusion Medicine Unit, Inter-Company Department of Transfusion Medicine (IDTM) of Local Health Unit (LHU) of Lecce, Vito Fazzi Hospital, 73100, Lecce, Italy. sticchidamiani@gmail.com.
Antonella Zizza *Institute of Clinical Physiology, National Research Council, Via Prov.Le Lecce-Monteroni, 73100, Lecce, Italy. zizza@ifc.cnr.it.ORCID http://orcid.org/0000-0001-5598-8499
Federico Banchelli *Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.ORCID http://orcid.org/0000-0003-0499-2505
Maddalena GiganteImmunohaematology and Transfusion Medicine Unit, Inter-Company Department of Transfusion Medicine (IDTM) of Local Health Unit (LHU) of Bari, S. Paolo Hospital, Bari, Italy.
Maria Lucia De FeoImmunohaematology and Transfusion Medicine Unit, Inter-Company Department of Transfusion Medicine (IDTM) of Local Health Unit (LHU) of Foggia, Ospedali Riuniti of Foggia, Foggia, Italy.
Angelo OstuniImmunohaematology and Transfusion Medicine Unit, Policlinico of Bari, Bari, Italy.
Valerio MarinelliImmunohaematology and Transfusion Medicine Unit, Inter-Company Department of Transfusion Medicine (IDTM) of Local Health Unit (LHU) of Lecce, Vito Fazzi Hospital, 73100, Lecce, Italy.
Serena QuagnanoImmunohaematology and Transfusion Medicine Unit, Inter-Company Department of Transfusion Medicine (IDTM) of Local Health Unit (LHU) of Lecce, Vito Fazzi Hospital, 73100, Lecce, Italy.
Pierpaolo NegroImmunohaematology and Transfusion Medicine Unit, Inter-Company Department of Transfusion Medicine (IDTM) of Local Health Unit (LHU) of Lecce, Vito Fazzi Hospital, 73100, Lecce, Italy.ORCID http://orcid.org/0000-0001-6156-0413
Nicola Di RenzoImmunohaematology and Transfusion Medicine Unit, Inter-Company Department of Transfusion Medicine (IDTM) of Local Health Unit (LHU) of Lecce, Vito Fazzi Hospital, 73100, Lecce, Italy.ORCID http://orcid.org/0000-0003-0604-6934
Marcello GuidoLaboratory of Hygiene, Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy.ORCID http://orcid.org/0000-0002-7907-2677
Seroprevalence COVID Blood Donors Study Group
Ospedale Vito Fazzi · ITInstitute of Sciences of Food Production · ITOspedali Riuniti di Foggia · ITUniversity of Modena and Reggio Emilia · ITUniversity of Salento · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This is an observational multicentric cross-sectional study aiming at assessing the association between ABO blood groups and SARS-CoV-2 seroprevalence among the blood donors in Puglia region. Data on ABO and Rh blood groups and demographic characteristics were obtained from Blood Bank Information System. All donors were screened for SARS-CoV-2 IgG antibodies. Comparison of seroprevalence among blood groups and the association between the recorded variables and seroprevalence were evaluated. A total of 35,709 donors from 22 centers were included, with a seroprevalence of 6.8%. The distribution of ABO phenotypes was blood type O (46.8%), A (34.0%), B (14.7%), and AB (4.5%). Among the 2416 donors reactive for SARS-CoV-2 IgG, the prevalent phenotype was blood type O (43.1%), followed by A (37.7%), B (14.2%), and AB (5%). The seroprevalence of phenotype A and AB was 7.5%, followed by B (6.5%) and O (6.2%). According to the adjusted analysis, there was an increase in seroprevalence in groups A and AB, compared to group O, and an increase in males compared to females. A possible effect modification was observed after stratifying for sex (p = 0.0515). A significantly lower prevalence of blood type O was found compared to A and AB, whereas no association was observed between Rh factor and seroprevalence. We hypothesized that the A antigen present in blood type A and AB can play a role in the binding of SARS-CoV-2 to ACE2 receptors, resulting in an increased risk of infection. Furthermore, natural anti-A/anti-B antibodies produced in group O could block viral adhesion to cells and explain a lower risk of infection.

Indexed as

Blood DonorsCOVID-19ABO Blood-Group SystemAntibodies, ViralAntilymphocyte SerumCross-Sectional StudiesFemaleHumansImmunoglobulin GMaleSARS-CoV-2Seroepidemiologic StudiesABO Blood-Group SystemAntibodies, ViralAntilymphocyte SerumImmunoglobulin GABO blood typeBlood donorsCOVID-19SARS-CoV-2 infection

Identifiers

PMID37442822
PMCPMC10492875
OpenAlexW4384154630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.